HedgeChatter

  • Home /
  • Tag Archives

MELA

MELA Sciences Predictive Probability Study Supports Increased Diagnostic Accuracy by Dermatologists for Melanoma

[Marketwired] – MELA Sciences, Inc. , developer of the MelaFind® system, an optical diagnostic device approved for use in the U.S. and the European Union to assist dermatologists in melanoma diagnosis, today announced … moreView todays social media effects on MELAView the latest stocks trending across Twitter. Click to view dashboardSee who MELA is hiring next, click here to view […]

May 8, 2014 Bystocknews , Comments Off on MELA Sciences Predictive Probability Study Supports Increased Diagnostic Accuracy by Dermatologists for Melanoma read more

MELA Sciences’ CEO Discusses Q4 2013 Results – Earnings Call Transcript

[at Seeking Alpha] – Rosemary Crane Thanks, Toni. Good afternoon and thank you for joining us on today’s call. I’ve been with the company since November 2013. moreView todays social media effects on MELAView the latest stocks trending across Twitter. Click to view dashboardSee who MELA is hiring next, click here to view […]

March 17, 2014 Bystocknews , Comments Off on MELA Sciences’ CEO Discusses Q4 2013 Results – Earnings Call Transcript read more

Rose Crane, CEO of Melanoma Diagnostics Provider, MELA Sciences, to Be Interviewed Live Today on Clear Channel Business Talk Radio DFW1190AM

[Marketwired] – MELA Sciences, Inc. , developer of MelaFind®, an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, announced that its CEO Rose Crane will be interviewed live today … moreView todays social media effects on MELAView the latest stocks trending across Twitter. Click to view dashboardSee who MELA is hiring next, click here to view […]

February 25, 2014 Bystocknews , Comments Off on Rose Crane, CEO of Melanoma Diagnostics Provider, MELA Sciences, to Be Interviewed Live Today on Clear Channel Business Talk Radio DFW1190AM read more

Melanoma Diagnostic Provider, MELA Sciences Receives 180-Day Extension to Meet NASDAQ Minimum Bid Price

[Business Wire] – MELA Sciences, Inc. , developer of MelaFind®, an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, has filed a Form 8-K providing full details of a 180-day grace period it has received from NASDA moreView todays social media effects on MELAView the latest stocks trending across Twitter. Click to view dashboardSee who MELA is […]

February 24, 2014 Bystocknews , Comments Off on Melanoma Diagnostic Provider, MELA Sciences Receives 180-Day Extension to Meet NASDAQ Minimum Bid Price read more

MELA Presents New Data That Reinforces the Importance of MelaFind® as a Diagnostic Tool at AAD Meeting

[at noodls] – Data Shows that MelaFind® Significantly Improves Melanoma Detection Rates of Resident Dermatologists IRVINGTON, NY, March 18, 2013 – Research presented by MELA Sciences, Inc. (NASDAQ: MELA) at the 71stAnnual … moreView todays social media effects on MELAView the latest stocks trending across Twitter. Click to view dashboardSee who MELA is hiring next, click here to view […]

March 18, 2013 Bystocknews , Comments Off on MELA Presents New Data That Reinforces the Importance of MelaFind® as a Diagnostic Tool at AAD Meeting read more

Epidemic Increases In Melanoma Rates Three Of Four Americans Surveyed Have Never Had Skin Cancer Examination

[at noodls] – Survey Commissioned by MELA Sciences, Inc. Illustrates Need to Expand Skin Cancer Detection Habits in U.S. IRVINGTON, NY, February 21, 2013 – MELA Sciences, Inc. (NASDAQ: MELA)….This is an abstract of … moreView todays social media effects on MELAView the latest stocks trending across Twitter. Click to view dashboardSee who MELA is hiring next, click here to […]

February 21, 2013 Bystocknews , Comments Off on Epidemic Increases In Melanoma Rates Three Of Four Americans Surveyed Have Never Had Skin Cancer Examination read more